Congratulations Kalina!!

2018-11-09T14:01:03+00:0009/11/2018|Categories: Events, News|Tags: , , , |

We would like to give the warmest and biggest congratulations to our Board Officer and Cluster Headache Delegate, Kalina Tyminski!!! We are beyond proud to announce that Mrs. Tyminski just received a Certificate of Commendation for Young Volunteer Advocate from the EFNA Advocacy Awards 2018.  Thank you for all your hard work, dedication, outstanding contribution and always enormous effort for our cause. Keep the great work!

Master of Headache Disorder

2018-10-26T14:01:11+00:0026/10/2018|Categories: News|Tags: , , |

Copenhagen University is now offering a Master on Headache Disorders. It´s a continuing professional development programme for healthcare professionals. The programme requires a minimum of 6 individual visits to Copenhagen, Denmark over a two-year period: Modules 1 to 4 are organized with an e-learning self-study period followed by one week of face-to-face sessions at University of Copenhagen. Module 5 is a three week clinical course at the Danish Headache Centre. Module 6 is the final module. This module is comprised of a master’s thesis, which is completed with an oral examination in Denmark. This medical master’s programme consists of modules covering headache [...]

Migraine Association of Ireland

2018-10-19T12:26:46+00:0019/10/2018|Categories: Associations, Events, News|Tags: , , |

Migraine Awareness Week 2018 MAI held an accredited Health Care Professional Seminar, during which two international speakers presented on Migraine: Diagnosis and Treatment, and the Development of the new Anti-CGRP medication. Prof. Lars Edvinsson and Prof. Allan Purdy, both members of the IHS, followed this up by doing a webinar for members of the Irish Pharmacy Union In conjunction with this, MAI has been running a campaign ‘A Headache a Day is not Okay’ to encourage migraineurs to consult with their pharmacist regarding medication and treatment for migraine, while avoiding Medication Overuse Headache. MAI is also encouraging pharmacists to build [...]

#MoveForMigraine

2018-10-18T12:00:15+00:0018/10/2018|Categories: Associations, News|Tags: , |

#MoveForMigraine Migraine remains an overlooked and misunderstood condition in many parts of Europe, including Belgium. The disease suffers from a lack of recognition and understanding, even from the first concerned parties (patients, caregivers, employers, etc.). This comes at a significant burden for the patients and at a high cost for society (1,650,000 working days lost every year in Belgium). #Move4Migraine is an independent, multidisciplinary platform that brings patients and actors from the healthcare, labour world and civil society together. Mik Ver Berne, chair of the Belgian Headache Association and member of the European Migraine Headache Alliance (EMHA), participates in the [...]

Lilly Receives Positive CHMP Opinion for Emgality

2018-10-17T12:24:24+00:0017/10/2018|Categories: Industry, News|Tags: , , , , |

INDIANAPOLIS, Sept. 21, 2018 Lilly Receives Positive CHMP Opinion for EmgalityTM (galcanezumab) for the Prophylaxis of Migraine in Adults Eli Lilly and Company announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Emgality TM (galcanezumab) for the prophylaxis of migraine in adults who have at least four migraine days per month. TM In June 2018, Lilly announced the intended brand name, Emgality, was conditionally accepted by the U.S. Food and Drug Administration (FDA). Emgality is a humanized monoclonal antibody specifically designed to bind to the calcitonin gene-related peptide (CGRP), blocking its [...]

European Civic Prize on Chronic Pain

2018-10-16T17:43:16+00:0016/10/2018|Categories: Events, News|Tags: , , , |

Active Citizenship Network launch the second edition of the bi-annual research-project at the European level “EU Civic Prize on Chronic Pain - Collection of good practices” with the aim to continue to give evidence on existing good practices in several European countries in terms of the struggle against pain. Aims of the project Giving continuity to the successful collection of good practices “EU Civic Prize on Chronic Pain - Collection of good practices” - First Edition. Enriching European and national experiences, expertise, data and benchmarking on chronic pain. Fostering the multi-stakeholder platform of operators of good practices on pain, created in [...]

Patient Solidarity Day 2018

2018-10-16T17:32:21+00:0016/10/2018|Categories: Events, News|Tags: , , , , |

On Friday 7 December 2018, patient advocates and stakeholders from all world regions will stand together, united in a celebration of Patient Solidarity Day (PSD). This year’s theme is about ‘Safe Medication and Healthcare for All’ and it aims to raise awareness on these critical global public health issues and advocate for access to safe, quality and appropriate medicines and treatments as warranted by patients' conditions. The Key Messages about Patient Solidarity Day: This Patient Solidarity Day patient advocates across the globe are coming together in solidarity to raise awareness on and advocate for access to safe medication and healthcare for all. Patient exposure [...]

Lilly’s Emgality Approved

2018-10-15T18:00:28+00:0015/10/2018|Categories: Industry, News|Tags: , , , , |

INDIANAPOLIS, Sept. 27, 2018 Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved Emgality™ (galcanezumab-gnlm) 120 mg injection for the preventive treatment of migraine in adults. Emgality offers a once-monthly, self-administered, subcutaneous injection. Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients. Emgality will be available to patients shortly after approval. Patients with commercial insurance are candidates to receive Emgality for up to 12 months free as part of Lilly's patient support program (governmental beneficiaries excluded; subject to terms and conditions*). Emgality will be available for pickup at retail pharmacies. Migraine [...]

EMHA New Corporate Website

2018-10-05T13:56:15+00:0005/10/2018|Categories: News|Tags: , , |

European Migraine and Headache Alliance (EMHA) has launched a new version of its corporate website: www.emhalliance.org The website has a number of new features to improve user experience, including: A complete refreshed homepage where we have implemented a calendar in which users can see the great activity of EMHA for every month, all the congresses, events, meetings and acts we will be assisting to. A new slider which shows the events we have participated in with a brief description A new space called EMHAnews (in substitution of EMHA Magazine) in which we will be updating more internal news of the organization [...]

The #MigrainePose “Trend”

2018-09-11T17:39:27+00:0011/09/2018|Categories: News|Tags: , , |

  How can this even be a trend!!!!???? Headache Pose? Migraine Pose? What is this supposed to mean? Migraine is not a pose but a neurological disorder involving nerve pathways and brain chemicals, which leaves completely disabled anyone who suffers an attack for an uncertain period of time. It´s very sad and outrageous that such an important magazine like ELLE.com publishes an article which undermines the real importance of such a severe condition. We were shocked when we saw this and thought how relevant it was to share it, this publication does no other thing rather than increasing the stigma of migraine. The images [...]

We and our partners use cookies, to collect browsing data to give you the best online experience and to personalize the content, play multimedia content, interact with social networks and perform browsing analytics. If you continue browsing we understand you accept the use of such technology. For more information visit our cookies policy Find out more

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close